Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GZMO -- Ignore unavailable to you. Want to Upgrade?

To: D.Lu who wrote (253)	4/19/2000 9:06:00 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 438

I listened in as well, a handful of the fusion trials coming, plus one vaccine which will be based on an antigen found with SAGE--that one late this year. I did not take notes. Not sure what the point was about Boston versus German fusion tech, if one works better than the other than why not. And they already have, what was it, seven for 23 with that spectacular response... I did snag the March PNAS paper...Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells . For $15 you can get access to PNAS for a week. My desktop is covered with PDF's, although it is pretty much greek to me.